⌘K
t
Haleon plc: Director Declaration
21 January 2026: Haleon plc (LSE/NYSE: HLN) announces that Dawn Allen, Chief Financial Officer, has been appointed Chair of the Audit & Risk Committee of ITV plc with effect from 5 March 2026.
Dawn has served as a Non‑Executive Director of ITV plc and a member of its Audit & Risk Committee since 2 October 2023.
This notification is made in accordance with the requirements of Listing Rule 6.4.9R(2).
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
Haleon plc announced on 21 January 2026 that Dawn Allen, its Chief Financial Officer, has been appointed Chair of the Audit & Risk Committee of ITV plc. This appointment is effective from 5 March 2026. Allen has served as a Non-Executive Director of ITV plc and a member of its Audit & Risk Committee since 2 October 2023.
| Date | 21 Jan 2026 |
| Time | 14:45:00 |
| Category | Miscellaneous |
| ID | 8295P |